SYNGIS' AX200 gets EU orphan status for ALS
German drugmaker SYNGIS Pharma AG says that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products has recommended orphan designation for AX200, its candidate amyotrophic lateral sclerosis treatment. The drug, which is a therapeutic protein specifically developed for the treatment of neurodegenerative disorders, counteracts neuronal cell death, decelerating the progression of ALS.
SYNGIS said that laboratory trials had shown that AX200 helped prevent the degradation of motorneurones, leading to increased maintenance of muscular strength over time. The firm added that the drug also appears to stimulate regenerative process within these cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze